Century Therapeutics (IPSC) Common Equity (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Common Equity data on file, last reported at $264.7 million in Q1 2026.

• On a quarterly basis, Common Equity rose 10.11% year-over-year to $264.7 million in Q1 2026; TTM through Mar 2026 was $264.7 million, a 10.11% increase from a year earlier, with the FY2025 full-year figure at $158.9 million, down 1.5% from the prior year.
• Common Equity for Q1 2026 stood at $264.7 million, up from $158.9 million in the prior quarter.
• Over the last five years, Common Equity for IPSC reached as high as $386.7 million in Q1 2022 and fell as low as $158.9 million in Q4 2025.
• Historically, Common Equity has averaged $242.0 million across 5 years, with a median of $222.1 million in 2024.
• Across the five-year window, Common Equity jumped 522.32% in 2022 and tumbled 38.97% in 2023, its largest moves.
• Year by year, Common Equity stood at $302.7 million in 2022, then tumbled by 38.97% to $184.8 million in 2023, then retreated by 12.66% to $161.4 million in 2024, then dropped by 1.5% to $158.9 million in 2025, then jumped by 66.57% to $264.7 million in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $264.7 million in Q1 2026, $158.9 million in Q4 2025, and $176.3 million in Q3 2025.